Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases III Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST III Trial - REDUCE POLYTECH RCT) Comparison of the Efficacy and Safety of Biostable Polymer Everolimus-eluting Coronary Stent System (Promus PremierTM) With Biodegradable Polymer Biolimus-eluting Coronary Stent System (Biomatrix®, Biomatrix Flex® and Nobori®) and Conventional Dose Prasugrel Therapy With Reduced Dose Prasugrel Therapy in Acute Coronary Syndrome Patients Treated With Percutaneous Coronary Intervention.

Trial Profile

Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases III Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST III Trial - REDUCE POLYTECH RCT) Comparison of the Efficacy and Safety of Biostable Polymer Everolimus-eluting Coronary Stent System (Promus PremierTM) With Biodegradable Polymer Biolimus-eluting Coronary Stent System (Biomatrix®, Biomatrix Flex® and Nobori®) and Conventional Dose Prasugrel Therapy With Reduced Dose Prasugrel Therapy in Acute Coronary Syndrome Patients Treated With Percutaneous Coronary Intervention.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Everolimus (Primary) ; Prasugrel
  • Indications Coronary artery restenosis
  • Focus Adverse reactions
  • Acronyms HOST-III-REDUCE-POLYTECH-RCT
  • Most Recent Events

    • 01 Jan 2015 Status changed from not yet recruiting to recruiting, as per the study design presented.
    • 07 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top